Citations

Showing 10 of 108135 citations.

Novel biomarkers for cholangiocarcinoma: how can it enhance diagnosis, prognostication, and investigational drugs? Part-1
Sinniah, Ranuka , Shapses, Mark S, Ahmed, Mohammad Umar, Chandana, Sreenivasa R , Shapses, Mark A., Ahmed, Mohammad Umar, Babiker, Hani M.

Mayo Clinic

Expert Opinion on Investigational Drugs | September 28, 2021 | Volume: 30 | Issue: 10 | Pages: 1047-1056

10.1080/13543784.2021.1985461 | PMID 34579607 Get It

The Medical Management of Gastroesophageal Reflux Disease: A Narrative Review
Cortés, Pedro , Lukens, Frank , Cortés, Pedro , Lukens, Frank J., Kröner, Paul T.

Mayo Clinic

Journal of Primary Care & Community Health | September 28, 2021 | Volume: 12 | Issue: No issue available | Pages: No page available

10.1177/21501327211046736 | PMID 34581222 Get It

Objective The medical management of gastroesophageal reflux disease (GERD) continues to evolve. Our aim was to systematically assess the literature to provide an updated review of the evidence on lifestyle modifications and pharmacological therapy for the management of GERD. Background The cornerstones of GERD medical management consist of lifestyle modifications and pharmacologic agents. Most recently, evidence has emerged linking anti-reflux pharmacologic therapy to adverse events, such as kidney injury, metabolic bone disease, myocardial infarction, and even dementia, among others. Methods A systematic search of the databases of PubMed/MEDLINE, Embase, and Cochrane Library was performed for articles on the medical management of GERD between inception and March 1, 2021. Conclusion Although pharmacological therapy has been associated with potential adverse events, further research is needed to determine if this association exists. For this reason, lifestyle modifications should be considered first-line, while pharmacologic therapy can be considered in patients in whom lifestyle modifications have proven to be ineffective in controlling their symptoms or cannot institute them. Naturally, extra-esophageal causes for GERD-like symptoms must be considered on suspected high-risk patients and excluded before considering treatment for GERD.
Current directions in tau research: Highlights from Tau 2020
Sexton, Claire E. , Snyder, Heather M. , Boxer, Adam L. , Brannelly, Patrick , Brion, Jean‐Pierre , Buée, Luc , Cacace, Angela , Chételat, Gaël , Citron, Martin , DeVos, Sarah L. , Diaz, Kristophe , Feldman, Howard , Frost, Bess , Goate, Alison , Gold, Michael , Johnson, Keith A. , Kerwin, Diana , Mummery, Catherine J. , Mutamba, James, Quiroz, Yakeel T. , Rabinovici, Gil D. , Rommel, Amy, Shulman, Melanie , Toledo‐Sherman, Leticia , Weninger, Stacie, Wildsmith, Kristin R., Worley, Susan, Carrillo, María C. , Sexton, Claire , Patterson, Marc C. , Rabinovici, Gil D , Feldman, Howard H , Goate, Alison M , Beher, Dirk , Hyman, Bradley T. , Karch, Celeste M. , Koroshetz, Walter J. , Litvan, Irene , Morris, Huw R.

Mayo Clinic

Alzheimer's & Dementia | September 28, 2021 | Volume: 18 | Issue: 5 | Pages: 988-1007

10.1002/alz.12452 | PMID 34581500 Get It

AbstractStudies supporting a strong association between tau deposition and neuronal loss, neurodegeneration, and cognitive decline have heightened the allure of tau and tau‐related mechanisms as therapeutic targets. In February 2020, leading tau experts from around the world convened for the first‐ever Tau2020 Global Conference in Washington, DC, co‐organized and cosponsored by the Rainwater Charitable Foundation, the Alzheimer's Association, and CurePSP. Representing academia, industry, government, and the philanthropic sector, presenters and attendees discussed recent advances and current directions in tau research. The meeting provided a unique opportunity to move tau research forward by fostering global partnerships among academia, industry, and other stakeholders and by providing support for new drug discovery programs, groundbreaking research, and emerging tau researchers. The meeting also provided an opportunity for experts to present critical research‐advancing tools and insights that are now rapidly accelerating the pace of tau research.
Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease
Weiner, Michael W. , Aisen, Paul, DeCarli, Charles , Harvey, Danielle , Jack, Clifford R. , Jagust, William J. , Landau, Susan, Morris, John C. , Okonkwo, Ozioma C. , Perrin, Richard J. , Petersen, Ronald C. , Mindt, Mónica Rivera , Saykin, Andrew J. , Shaw, Leslie M. , Tosun, Duygu , Trojanowski, John Q. , Initiative, Alzheimer's Disease Neuroimaging, DeCarli, Charles , Jack, Clifford R , Saykin, Andrew J , Morris, John C , Harvey, Danielle J , Tosun, Duygu , Veitch, Dallas P. , Beckett, Laurel , Green, Robert C. , Toga, Arthur W. , Initiative, Alzheimer's Disease Neuroimaging

Mayo Clinic

Alzheimer's & Dementia | September 28, 2021 | Volume: 18 | Issue: 4 | Pages: 824-857

10.1002/alz.12422 | PMID 34581485 Get It

AbstractIntroductionThe Alzheimer's Disease Neuroimaging Initiative (ADNI) has accumulated 15 years of clinical, neuroimaging, cognitive, biofluid biomarker and genetic data, and biofluid samples available to researchers, resulting in more than 3500 publications. This review covers studies from 2018 to 2020.MethodsWe identified 1442 publications using ADNI data by conventional search methods and selected impactful studies for inclusion.ResultsDisease progression studies supported pivotal roles for regional amyloid beta (Aβ) and tau deposition, and identified underlying genetic contributions to Alzheimer's disease (AD). Vascular disease, immune response, inflammation, resilience, and sex modulated disease course. Biologically coherent subgroups were identified at all clinical stages. Practical algorithms and methodological changes improved determination of Aβ status. Plasma Aβ, phosphorylated tau181, and neurofilament light were promising noninvasive biomarkers. Prognostic and diagnostic models were externally validated in ADNI but studies are limited by lack of ethnocultural cohort diversity.DiscussionADNI has had a profound impact in improving clinical trials for AD.
Disability and Economic Loss Caused by Headache among Information Technology Workers in Korea
Kim, Byung‐Kun , Cho, Soo‐Jin , Kim, Changsoo , Sakai, Fumihiko , Dodick, David W. , Chu, Min Kyung , Kim, Chang Soo , Dodick, David W , Chu, Min Kyung

Mayo Clinic

Journal of Clinical Neurology | September 28, 2021 | Volume: 17 | Issue: 4 | Pages: 546

10.3988/jcn.2021.17.4.546 | PMID 34595863 Get It

Sequential changes in urinary biomarker levels in patients with cirrhosis and severe hepatorenal syndrome
Solé, Cristina , T., Ann , Solà, Elsa , Carol, Marta, Juanola, Adrià , Napoleone, Laura , Gratacós‐Ginès, Jordi , Bassegoda, Octavi , Cervera, Marta , Pérez, Martina , Rubio, Ana Belén, Avitabile, Emma , Graupera, Isabel , Pose, Elisa , Kamath, Patrick S. , Ma, Ann T , Gines, Pere , Fabrellas, Núria , Morales‐Ruiz, Manuel , Ginès, Pere

Mayo Clinic

Liver International | September 27, 2021 | Volume: 41 | Issue: 11 | Pages: 2729-2732

10.1111/liv.15069 | PMID 34569697 Get It

AbstractWhether tubular injury develops in patients with acute kidney injury owing to hepatorenal syndrome (AKI‐HRS) is controversial. We performed repeated measurements of biomarkers of tubular injury during a 14‐day period in 60 patients with cirrhosis and AKI (34 with AKI‐HRS meeting the classical definition of type 1 HRS and 26 with AKI owing to acute tubular necrosis, AKI‐ATN). Nineteen of 34 patients had resolution of AKI‐HRS, while the remainder had persistent AKI‐HRS. The persistence of AKI‐HRS was associated with remarkably high short‐term mortality. There were no significant differences in urinary NGAL or IL‐18 between patients with resolution vs those with persistent AKI‐HRS throughout the 14‐day period. By contrast, biomarker levels were significantly lower in AKI‐HRS, even if persistent, compared to AKI‐ATN. These findings are highly suggestive of lack of significant tubular injury in AKI‐HRS and could be of value in the clinical decision between combined liver–kidney or liver transplantation alone in patients with cirrhosis and AKI candidates to transplantation.
IFNα and β Mediated JCPyV Suppression through C/EBPβ-LIP Isoform
May, Dana , Bellizzi, Anna , Kassa, Workineh, Cipriaso, John M., Caocci, Maurizio, Wollebo, Hassen S. , Cipriaso, J. Marco

Mayo Clinic

Viruses | September 27, 2021 | Volume: 13 | Issue: 10 | Pages: 1937

10.3390/v13101937 | PMID 34696366 Get It

Polyomavirus JC (JCPyV) causes the demyelinating disease progressive multifocal leukoencephalopathy (PML). JCPyV infection is very common in childhood and, under conditions of severe immunosuppression, JCPyV may reactivate to cause PML. JC viral proteins expression is regulated by the JCPyV non-coding control region (NCCR), which contains binding sites for cellular transcriptional factors which regulate JCPyV transcription. Our earlier studies suggest that JCPyV reactivation occurs within glial cells due to cytokines such as TNF-α which stimulate viral gene expression. In this study, we examined interferon-α (IFNα) or β (IFNβ) which have a negative effect on JCPyV transcriptional regulation. We also showed that these interferons induce the endogenous liver inhibitory protein (LIP), an isoform of CAAT/enhancer binding protein beta (C/EBPβ). Treatment of glial cell line with interferons increases the endogenous level of C/EBPβ-LIP. Furthermore, we showed that the negative regulatory role of the interferons in JCPyV early and late transcription and viral replication is more pronounced in the presence of C/EBPβ-LIP. Knockdown of C/EBPβ-LIP by shRNA reverse the inhibitory effect on JCPyV viral replication. Therefore, IFNα and IFNβ negatively regulate JCPyV through induction of C/EBPβ-LIP, which together with other cellular transcriptional factors may control the balance between JCPyV latency and activation.
Clinically Distinct Subtypes of Acute Kidney Injury on Hospital Admission Identified by Machine Learning Consensus Clustering
Vaitla, Pradeep , Nissaisorakarn, Voravech , Mao, Michael A. , Genovez, Jose L. Zabala , Kattah, Andrea G. , Pattharanitima, Pattharawin , Vallabhajosyula, Saraschandra , Keddis, Mira T. , Kashani, Kianoush , Cheungpasitporn, Wisit , Nissaisorakarn, Voravech , Mao, Michael A , Pattharanitima, Pattharawin , Vallabhajosyula, Saraschandra , Dillon, John J, Kashani, Kianoush B , Cheungpasitporn, Wisit , Thongprayoon, Charat , Qureshi, Fawad , Dillon, John , Garovic, Vesna D.

Mayo Clinic

Medical Sciences | September 27, 2021 | Volume: 9 | Issue: 4 | Pages: 60

10.3390/medsci9040060 | PMID 34698185 Get It

Background: We aimed to cluster patients with acute kidney injury at hospital admission into clinically distinct subtypes using an unsupervised machine learning approach and assess the mortality risk among the distinct clusters. Methods: We performed consensus clustering analysis based on demographic information, principal diagnoses, comorbidities, and laboratory data among 4289 hospitalized adult patients with acute kidney injury at admission. The standardized difference of each variable was calculated to identify each cluster’s key features. We assessed the association of each acute kidney injury cluster with hospital and one-year mortality. Results: Consensus clustering analysis identified four distinct clusters. There were 1201 (28%) patients in cluster 1, 1396 (33%) patients in cluster 2, 1191 (28%) patients in cluster 3, and 501 (12%) patients in cluster 4. Cluster 1 patients were the youngest and had the least comorbidities. Cluster 2 and cluster 3 patients were older and had lower baseline kidney function. Cluster 2 patients had lower serum bicarbonate, strong ion difference, and hemoglobin, but higher serum chloride, whereas cluster 3 patients had lower serum chloride but higher serum bicarbonate and strong ion difference. Cluster 4 patients were younger and more likely to be admitted for genitourinary disease and infectious disease but less likely to be admitted for cardiovascular disease. Cluster 4 patients also had more severe acute kidney injury, lower serum sodium, serum chloride, and serum bicarbonate, but higher serum potassium and anion gap. Cluster 2, 3, and 4 patients had significantly higher hospital and one-year mortality than cluster 1 patients (p < 0.001). Conclusion: Our study demonstrated using machine learning consensus clustering analysis to characterize a heterogeneous cohort of patients with acute kidney injury on hospital admission into four clinically distinct clusters with different associated mortality risks.
The effect of omega-3 fatty acids on a biomarker of head trauma in NCAA football athletes: a multi-site, non-randomized study
Anzalone, Anthony J. , Carbuhn, Aaron F. , Askow, Andrew T. , Stone, Jason D. , Turner, Stephanie M., Hillyer, Lyn M., Luedke, Joel, Oliver, Jonathan M. , Anzalone, Anthony J , Askow, Andrew T , Heileson, Jeffery L. , W.L., David , Jagim, Andrew R.

Mayo Clinic

Journal of the International Society of Sports Nutrition | September 27, 2021 | Volume: 18 | Issue: 1 | Pages: No page available

10.1186/s12970-021-00461-1 | PMID 34579748 Get It

Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission
Shadman, Mazyar , Pasquini, Marcelo C. , Ahn, Kwang Woo , Chen, Yue , Turtle, Cameron J. , Hematti, Peiman , Cohen, Jonathon B. , Khimani, Farhad , Ganguly, Siddhartha , Munshi, Pashna N. , Beitinjaneh, Amer , Herrera, Alex F. , Sauter, Craig S. , Kharfan‐Dabaja, Mohamed A. , Pasquini, Marcelo , Herrera, Alex F , Kharfan-Dabaja, Mohamed A , Hamadani, Mehdi , Shadman, Mazyar , Hematti, Peiman , Turtle, Cameron J , Merryman, Reid W. , Yared, Jean A. , Locke, Frederick L. , Ahmed, Nausheen , Reagan, Patrick Michael , Hamadani, Mehdi

Mayo Clinic

Blood | September 27, 2021 | Volume: 139 | Issue: 9 | Pages: 1330-1339

10.1182/blood.2021013289 | PMID 34570879 Get It

Abstract The relative efficacy of autologous hematopoietic cell transplant (auto-HCT) vs chimeric antigen receptor T-cell (CAR-T) therapy in patients with diffuse large B-cell lymphoma (DLBCL) who achieve a partial remission (PR) after salvage chemotherapy is not known. Using the Center for International Blood & Marrow Transplant Research registry database, we identified adult patients with DLBCL who received either an auto-HCT (2013-2019) or CAR-T treatment with axicabtagene ciloleucel (2018-2019) while in a PR by computed tomography or positron emission tomography scan. We compared the clinical outcomes between the 2 cohorts using univariable and multivariable regression models after adjustment for relevant baseline and clinical factors. In the univariable analysis, the 2-year progression-free survival (52% vs 42%; P = .1) and the rate of 100-day nonrelapse mortality (4% vs 2%; P = .3) were not different between the 2 cohorts, but consolidation with auto-HCT was associated with a lower rate of relapse/progression (40% vs 53%; P = .05) and a superior overall survival (OS) (69% vs 47%; P = .004) at 2 years. In the multivariable regression analysis, treatment with auto-HCT was associated with a significantly lower risk of relapse/progression rate (hazard ratio = 1.49; P = .01) and a superior OS (hazard ratio = 1.63; P = .008). In patients with DLBCL in a PR after salvage therapy, treatment with auto-HCT was associated with a lower incidence of relapse and a superior OS compared with CAR-T. These data support the role of auto-HCT as the standard of care in transplant-eligible patients with relapsed DLBCL in PR after salvage therapy.